AOD-9604 is a peptide fragment derived from the C-terminal region of human growth hormone, specifically designed to isolate the fat-metabolic activity of GH from its growth-promoting effects.
Research Applications
Fat metabolism, obesity research, cartilage repair studies, and metabolic research without IGF-1 elevation.
Dosage Information (Research Use)
Clinical trial doses: 250-500 mcg/day subcutaneously. Research use only.
Reconstitution & Handling
Standard BAC water reconstitution.
Half-Life & Pharmacokinetics
Short — similar to other GH fragment peptides.
Reported Observations in Literature
Generally well-tolerated in clinical trials. No significant adverse effects reported. Does not affect blood glucose or IGF-1 levels.
Key Research References
- Heffernan MA, et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology. 2001